Wird geladen...

ATIM-25. IMMUNOLOGICAL ACTIVATION IN RESPONDING PATIENTS WITH RECURRENT HGG AFTER TREATMENT WITH TOCA 511 & TOCA FC: RESULTS FROM A PHASE 1 TRIAL

A dose-escalation clinical study (NCT01470794) using a retroviral replicating vector (RRV), Toca 511 (vocimagene amiretrorepvec), in combination with oral Toca FC (extended-release 5-fluorocytosine, 5-FC) is ongoing to evaluate safety, mechanism of action, and preliminary efficacy of this investigat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Ostertag, Derek, Accomando, William, Hogan, Daniel, Diago, Oscar, Gammon, Dawn, Haghighi, Ali, Mitchell, Leah, Rodriguez-Aquirre, Maria, Cloughesy, Timothy, Kalkanis, Steven, Mikkelsen, Tom, Landolfi, Joseph, Chen, Clark, Vogelbaum, Michael, Gruber, Harry, Das, Asha, Jolly, Douglas
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2017
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691911/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.120
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!